RESEARCH MONOGRAPH · KDC-MN-388

Progesterone (Research)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

82/100

Endogenous progestogen with neurosteroid effects that the field is still catching up to

Progesterone is the principal endogenous progestogen, produced primarily by the corpus luteum and placenta, and historically thought of mainly through its uterine and reproductive roles. The more interesting modern story is the neurosteroid one. Progesterone is metabolized to allopregnanolone by 5-alpha-reductase and 3-alpha-HSD, and allopregnanolone is a positive allosteric modulator at GABA-A receptors with anxiolytic and anticonvulsant activity.

That neurosteroid axis is why brexanolone (synthetic allopregnanolone, FDA-approved 2019) and zuranolone (oral allopregnanolone analog, approved 2023) exist as postpartum depression therapies. Both are downstream of progesterone metabolism. The translation of the underlying biology has been slow but is now happening in real time.

The classical clinical literature is the progesterone hormone replacement work, including the early-luteal-phase support in fertility medicine, the perimenopausal vasomotor work, and the more controversial 17-OHP-caproate preterm-birth program (which failed its confirmatory trial and was pulled in 2023). The reproductive endocrinology applications are solid, the broader hormone therapy use is more nuanced and depends heavily on whether you're using oral micronized progesterone (Prometrium), vaginal forms, or synthetic progestins like medroxyprogesterone acetate that have very different receptor profiles.

What we like for research is that progesterone gives you access to multiple downstream pharmacologies through one parent molecule. PR agonism, GR partial agonism, MR antagonism (which is why it competes with aldosterone), neurosteroid synthesis. Different in vivo questions probe different branches of that tree.

What people miss: medroxyprogesterone acetate (Provera, used in WHI and most synthetic progestin contraceptives) is pharmacologically very different from natural progesterone. The WHI breast cancer signal was probably driven much more by MPA than by the estradiol arm. The micronized natural progesterone literature looks much cleaner. This distinction matters enormously and rarely gets explained well in summary articles.

Sourcing is fine. Progesterone is a high-volume pharmaceutical raw material, HPLC purity is reliable, stability is good in solid form. Solubility is poor in water, standard steroid solvent system (DMSO, ethanol, or oil vehicle).

Evidence: 88
Mechanism: 88
Reliability: 85
Safety: 78
Sourcing: 80
Value: 75
Signal: 75
Staying power: 88

Plain-language summary Intrigue 65 / 100

Progesterone is the principal endogenous progestogen, built from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (in pregnancy) placenta. It activates the progesterone receptor with high affinity and also has interesting side effects: it antagonizes mineralocorticoid receptors (driving sodium loss) and its metabolite allopregnanolone is a powerful positive modulator of GABA-A receptors (driving sedation). Approved for menopausal hormone therapy paired with estrogen for endometrial protection, IVF luteal support, secondary amenorrhea, and preterm birth prevention. Oral micronized progesterone hits the liver hard and produces sedating allopregnanolone, while vaginal and transdermal forms give cleaner PR effects. Plasma half-life of the parent is short (5 to 20 minutes). Canonical PR agonist. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous progestogen / PR agonist

The principal endogenous progestogen; a progesterone receptor agonist with luteal phase, gestational, and neurosteroid functions.

Abstract

Progesterone (pregn-4-ene-3,20-dione; CAS 57-83-0; molecular formula C21H30O2; molecular weight 314.46) is the principal endogenous progestogen, biosynthesized from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (during pregnancy) placenta. The compound is a high-affinity progesterone receptor (PR) agonist with secondary effects at the glucocorticoid receptor (mineralocorticoid antagonism contributing to natriuretic effects) and at GABA-A receptors (the pregnanolone metabolite is a positive allosteric modulator producing sedation). Approved indications: menopausal hormone therapy (combined with estrogen for endometrial protection in women with intact uterus), assisted reproductive technology luteal support, secondary amenorrhea, and prevention of preterm birth (intramuscular formulation). Oral micronized progesterone (Prometrium) is highly subject to first-pass metabolism producing the sedating allopregnanolone metabolite; vaginal and transdermal forms produce more direct PR effects with less sedation. Plasma half-life is short (5 to 20 minutes for parent; metabolites variable). Used as the canonical PR agonist in research.

Mechanism of action

Progesterone receptor agonist; secondary glucocorticoid receptor activity (mineralocorticoid antagonism) and GABA-A potentiation via allopregnanolone metabolite.

Reported research dose ranges

Reported research dose ranges vary across the published literature.

References

Stanczyk FZ, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013.
Fischer Walker CL, et al. Progesterone and 17-OH progesterone caproate for prevention of preterm birth. Obstet Gynecol 2017.
Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 2005.

Read the full monograph

Available as a research-use-only PDF download.

KDC-MN-388

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Progesterone (Research)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs